National Research Corporation Stock Downgraded (NRCIB)
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- NATIONAL RESEARCH CORP has improved earnings per share by 14.3% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, NATIONAL RESEARCH CORP increased its bottom line by earning $4.34 versus $3.40 in the prior year. This year, the market expects an improvement in earnings ($4.79 versus $4.34).
- The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Health Care Providers & Services industry average. The net income increased by 16.1% when compared to the same quarter one year prior, going from $3.85 million to $4.47 million.
- The gross profit margin for NATIONAL RESEARCH CORP is rather high; currently it is at 58.90%. Regardless of NRCIB's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, NRCIB's net profit margin of 17.94% significantly outperformed against the industry.
- NRCIB's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 57.11%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Although its share price is down sharply from a year ago, do not assume that it can now be tagged as cheap and attractive. The reality is that, based on its current price in relation to its earnings, NRCIB is still more expensive than most of the other companies in its industry.
-- Written by a member of TheStreet Ratings Staff
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.